Almost all of the methylation sites that were significantly associated with ischemic stroke in stage one were significant in stage two, except for 4 sites in TBX2 and 1 site in TTBK1. Additionally, 89 sites that did not pass the significance threshold in stage one were significant in stage two. Here, TBX2 is linked to ischemic stroke.